Subscribe to Newsletter
Business & Regulation Business Practice, Trends & Forecasts

Pfizer-Fuelled Rumors

In early February, Pfizer announced that it would acquire Hospira for around $17 billion. Hospira’s shareholders are set to profit from the deal, with Pfizer paying $90 per share, a 40 percent premium, and netting Hospira CEO F. Michael Ball an estimated $80 million payout (1).

The merger will substantially boost Pfizer’s portfolio, particularly in the emerging biosimilars market. Especially given that a couple of weeks after the announcement, Hospira launched a generic version of J&J’s Remicade (infliximab) in several European countries. The FDA will consider in March whether to approve the drug in the US.

The news has raised plenty of speculation in the pharmaceutical and business press. Most analysts agree that Pfizer is plotting futher acquisitions in the coming months, with one article touting GlaxoSmithKline and Actavis as potential targets (2). The deal is also being seen by some, including David Crow at the Financial Times (3), as another indication of a long-term plan to split Pfizer’s generic and brand name portfolios into separate companies. A split has certainly been mentioned as a possibility by Pfizer CEO Ian Read in the past, but only time will tell.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. J. Cahill, “Hospira CEO Ball‘s Richest Payday Ever”, Crain’s Chicago Business (11 February 2015),
  2. C. Swanson, “Deal-Hungry Pfizer Won‘t Stop With Hospira; Who Could Be Next?”, The Motley Fool (16 February 2015),
  3. D. Crow, “Pfizer’s $17Bn Hospira Buy Could Lead To Break-Up”, The Financial Times (5 February 2015),
About the Author
Charlotte Barker

As an Editor at Texere, I’m working closely with our audience to create vibrant, engaging content that reflects the hard work and passion that goes into bringing new medicines to market. I got my start in biomedical publishing as a commissioning editor for healthcare journals and have spent my career covering everything from early-stage research to clinical medicine, so I know my way around. And I can’t think of a more interesting, challenging or important area to be working in.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine